Anti-S1 MERS-COV IgY Specific Antibodies Decreases Lung Inflammation and Viral Antigen Positive Cells in the Human Transgenic Mouse Model
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 and causes severe and often fatal acute respiratory illness in humans. No approved prophylactic and therapeutic interventions are currently available. In this study, we have developed egg yolk antibodies (immunoglobul...
Main Authors: | Aymn T. Abbas, Sherif A. El-Kafrawy, Sayed Sartaj Sohrab, Ashraf A. Tabll, Ahmed M. Hassan, Naoko Iwata-Yoshikawa, Noriyo Nagata, Esam I. Azhar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/4/634 |
Similar Items
-
Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection
by: Sherif A. El-Kafrawy, et al.
Published: (2021-05-01) -
MERS-CoV
by: Beuy Joob, et al.
Published: (2014-09-01) -
MERS-CoV: Bridging the Knowledge Gaps
by: Abdullah Balkhair, et al.
Published: (2014-05-01) -
Communicating about the Middle East respiratory syndrome outbreak to the international community and in-country foreigners, Republic of Korea, 2015
by: Minwon Lee, et al.
Published: (2016-02-01) -
The Struggle Against MERS-CoV (The Novel Coronavirus)
by: Abdullah Balkhair, et al.
Published: (2013-07-01)